[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354598-105":59,"doc-detail-354598-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","in-vitro-characterization-of-a-bispecific-anti-pd-1ctla-4-single-chain-diabody-for-cancer-immunotherapy","In vitro characterization of a bispecific anti-(PD-1/CTLA-4) single-chain diabody for cancer immunotherapy","","The study develops a bispecific single-chain diabody engineered to simultaneously target PD-1 and CTLA-4 for cancer immunotherapy. The protein is expressed in a bacterial system, purified by affinity methods, and characterized for molecular size and antigen-binding behavior using SDS-PAGE, western blotting, and flow cytometry with PD-1/CTLA-4 ligands. It selectively binds PD-1/CTLA-4 expressing cells and blocks PD-1/PD-L1 and CD86/CTLA-4 interactions. In T-cell activation assays, it enhances IL-2 and IFN-γ secretion dose-dependently, reverses PD-L1 suppression of ConA-stimulated PBMCs, and increases proliferation and cytokine release in MLR assays, supporting further in vitro and in vivo evaluation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/in-vitro-characterization-of-a-bispecific-anti-pd-1ctla-4-single-chain-diabody-for-cancer-immunotherapy/354598/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/in-vitro-characterization-of-a-bispecific-anti-pd-1ctla-4-single-chain-diabody-for-cancer-immunotherapy/354598.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What bispecific protein is developed in this study?","Question",{"text":112,"@type":113},"A novel bispecific single-chain diabody engineered for simultaneous targeting of PD-1 and CTLA-4.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is the diabody characterized for size and binding?",{"text":117,"@type":113},"The expected ~55 kDa full-length His-tagged protein is confirmed by SDS-PAGE and western blotting, and binding properties are evaluated by flow cytometry with PD-1 and CTLA-4 ligands.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune effects does the bispecific diabody show in vitro?",{"text":121,"@type":113},"It selectively binds PD-1/CTLA-4 expressing cells, inhibits PD-1/PD-L1 and CD86/CTLA-4 interactions, increases IL-2 and IFN-γ in a dose-dependent manner, reverses PD-L1 suppression of ConA-stimulated PBMCs, and promotes T-cell proliferation and cytokine release in MLR assays.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354598,1790814634,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nIn vitro characterization of abispecific anti-(PD-1/CTLA-4) single-chain diabody for cancer immunotherapy  \nMohammad Ghoreishi1, Nafiseh Esmaeil2, Vajihe Akbari1􀀍 & Maryam Abbaspour1  \nImmunotherapy with a combination of anti-CTLA-4 and anti-PD-1 antibodies has exhibited promising results for the treatment of many kinds of cancers in clinical practice. In the present study, we developed a novel bispecific daibody for simultaneous targeting of PD-1 and CTLA-4 to induce antitumor immunity. The bispecific single-chain diabody was designed on the basis of the amino acid sequences of variable regions of anti-PD1 and anti-CTLA4 antibodies. After expression in the bacterial system and affinity purification, its binding properties alone or in the presence of PD-1 and CTLA-4 ligands were evaluated by flow cytometry. The expected molecular weight of the full-length Histagged protein was approximately 55 kDa, which was confirmed by SDS‒PAGE analysis and western blotting analysis. The bispecific diabody could selectively bind to cells expressing PD-1 and CTLA-4 and inhibit PD-1/PD-L1 and CD86/CTLA-4 interactions. This novel protein significantly increased IL-2 and IFN-γ secretion in a dose-dependent manner inT-cell activation experiments. Furthermore, it reversed the suppressive effect of PD-L1 on ConA-stimulated PBMCs. The diabody also led to a significant increase inT-cell proliferation and cytokine release in the MLR assay. This bispecific diabody can be considered a promising checkpoint inhibitor candidate, although more in vitro and in vivo biological function evaluations still need to be performed.  \nKeywords Immune checkpoint blockade, Single-chain diabody, CTLA-4, PD-1  \nImmune checkpoints are normal regulatory parts of the immune system that control the immune response and prevent autoimmune diseases1. However, tumor cells overexpress the ligand(s) of negative immune checkpoints to suppress the immune response and evade immune attack2. Accordingly, immune checkpoint blockade has been considered a therapeutic approach in cancer treatment. Programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4) are the two main targets of immune checkpoint blockade3. PD-1 is a receptor expressed on activated T cells and other immune cells, including B and natural killer (NK) cells. PD-1 binds to its ligand, B7-H1 (also known as PD-L1), which is expressed on the surface of dendritic cells (DCs), some myeloid cells, and tumor cells4. The interaction between PD-1 and PD-L1 results in a negative signal to activated T cells and inhibits antitumor responses5, although inhibiting this interaction with anti-PD-1 antibodies such as nivolumab could help to restore the antitumor activity ofT cells6. Activated T cells also express CTLA-4, which binds CD80/CD86 on the DC surface7. This interaction prevents the signaling of T-cell proliferation provided by the attachment of CD28 to CD80/CD868. Compared with CD28, CTLA-4 has a greater affinity for binding to CD80/CD86 and helps the immune system intentionally suppress T cells9. Targeting CTLA-4 with antibodies (e.g., ipilimumab) can also strengthen T-cell immunity against cancer10.  \nThe combination of PD-1 and CTLA-4 inhibitors has been shown to increase overall survival in clinical studies11, 12. The combination of ipilimumab and nivolumab has been approved by the FDA for the treatment of advanced melanoma, renal cell carcinoma, unresectable malignant pleural mesothelioma, and non-small cell lung cancer13. Resistance to single-agent immune checkpoint blockade (e.g., PD-1) often involves compensatory up-regulation of other immune checkpoints (e.g., lymphocyte activation gene-3 (LAG3) and CTLA-4), which may affect the efficacy of monotherapy14. However, combination therapy strategies and co-targeting of immune checkpoint with a bisepcific antibody may overcome this compensatory resistance and up","cbCaiqN7bp2NioBD","https://ap.wps.com/l/cbCaiqN7bp2NioBD","pdf",2400411,11,"English","# Background\n## Immune checkpoints and rationale for blockade\n## PD-1/PD-L1 and CTLA-4/CD80/CD86 pathways\n# Combination therapy and need for bispecific formats\n## Clinical context for PD-1 and CTLA-4 inhibition\n## Resistance and potential advantages of bispecific antibodies\n# Study design and characterization\n## Diabody design based on antibody variable regions\n## Expression, purification, and analytical validation\n## Binding assessment by flow cytometry\n# Functional assays\n## Inhibition of PD-1/PD-L1 and CTLA-4 interactions\n## T-cell activation: IL-2 and IFN-γ secretion\n## Reversal of PD-L1-mediated suppression\n## T-cell proliferation and MLR cytokine release\n# Conclusion and outlook","[{\"question\":\"What bispecific protein is developed in this study?\",\"answer\":\"A novel bispecific single-chain diabody engineered for simultaneous targeting of PD-1 and CTLA-4.\"},{\"question\":\"How is the diabody characterized for size and binding?\",\"answer\":\"The expected ~55 kDa full-length His-tagged protein is confirmed by SDS-PAGE and western blotting, and binding properties are evaluated by flow cytometry with PD-1 and CTLA-4 ligands.\"},{\"question\":\"What immune effects does the bispecific diabody show in vitro?\",\"answer\":\"It selectively binds PD-1/CTLA-4 expressing cells, inhibits PD-1/PD-L1 and CD86/CTLA-4 interactions, increases IL-2 and IFN-γ in a dose-dependent manner, reverses PD-L1 suppression of ConA-stimulated PBMCs, and promotes T-cell proliferation and cytokine release in MLR assays.\"}]","In vitro characterization of a bispecific anti-(PD-1/CTLA-4) single-chain diabody for cancer immunotherapy | PDF",1790112408,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cea285f9d788ec82e611cbebd13dceb.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8720535bd9aebfbb8893ead32b46ecc.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0ed0a358e2fb876fe0ea8d6b8633091.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f0a25a0c78b72db66fef11a0b9296ac.webp",980,1287]